Vor's cancer cell therapy gets on FDA fast track ahead of 2022 data drop

Vor's cancer cell therapy gets on FDA fast track ahead of 2022 data drop

Submitted by admin on September 11, 2021 - 10:28pm
Source: 
Fierce Biotech
News Tags: 
Vor Biopharma
JNJ
cell therapy
FDA
fast track
Headline: 
Vor's cancer cell therapy gets on FDA fast track ahead of 2022 data drop
snippet: 

The FDA has become the latest organization to validate the potential of Vor Biopharma’s approach to CRISPR-powered cell engineering, granting fast-track status to its lead asset shortly after Johnson & Johnson struck a deal to access the technology.

Do Not Allow Advertisers to Use My Personal information